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An estimated 203,500 new invasive cases of breast cancer are expected to occur among women in the United States during 2002. Breast cancer is the leading cancer site among American women and is the leading cause of cancer deaths among women ages 40-59. Up to 30% of these tumors have mutated epidermal growth factor receptors (EGFR, also known as HER or ErbBl). EGFR has been shown to be significantly overexpressed and deregulated in breast cancer, and the related HER2 receptor (also known as ErbB2) has shown gene amplification in 15-30% of invasive ductal breast cancers. The deregulation and consequent uncontrolled growth factor signaling of these receptors correlate with increasing tumor size, spreading of tumors to the lymph nodes and high grade metastasis. Since the constitutive activity of ErbB receptors promotes breast cancer, it is important to determine exactly how the ErbB receptors are regulated. In addition, understanding the regulation of this receptor may prove helpful in the development of new drug targets to combat breast cancer, which appears to be of increasing importance in light of recent studies which suggest that current therapies may not be as effective as once predicted.
In this proposal, we have focused on defining a novel way of regulating EGFR signaling. It has been shown that Hsp90 acts to stabilize EGFR at the membrane, and consequently may promote proper EGFR signaling. It has also been shown that Hsp90 is an acetylated protein, and that its acetylation status regulates its interaction with other proteins that promotes EGFR signaling. Deacetylated Hsp90 is able to bind EGFR, and stabilize EGFR to allow for the initiation of signaling cascades. Our lab has shown that a cytoplasmic deacetylase, HDAC6, associates with Hsp90 and EGFR. We hypothesize that HDAC6 might regulate the acetylation status of Hsp90 and consequently be involved in the EGFR signaling cascade. The characterization of HDAC6 as an Hsp90 deacetylase would provide an essential drug target to combat the deregulated activity of EGFR in breast tumors. Confirmation of this idea would allow for targeted chemotherapeutics to be developed that specifically inhibit HDAC6 in order to block the EGFR signaling cascade, thus stopping uncontrolled growth and metastasis. 
a. Characterizing the interaction between HDAC6, Hsp9Oand EGFR. (Months 1-8)
We have been able to show that HDAC6 interaction with Hsp90 increases upon stimulation with EGF (Data not shown). This interaction implies that Hsp90 effect on the stability of EGFR may be regulated by HDAC6. Additionally, Hsp90 is able to bind EGFR after ligand stimulation, thus implying the formation of a complex between these three proteins. We are currently exploring the possibility that these proteins interact in vitro in order to determine whether or not they bind directly or indirectly. Furthermore, we have found that the ubiquitinbinding domain of HDAC6 (BUZ Domain -Binder if Ubiquitin Zinc-finger domain) is required for HDAC6 binding to Hsp90 (Figure 1 -attached manuscript). This implies that (a) HDAC6 binding to Hsp90 is triggered by its association with ubiquitinated proteins (possibly EGFR), or (b) HDAC6 binds ubiquitinated Hsp90. These possibilities are currently being explored through the further examination of HDAC6 co-immunoprecipitations and examination of the ubiquitination status of the proteins involved. It does not appear that the ubiquitination status of Hsp90 modulates HDAC6 binding (data not shown).
b. Determining whether HDAC6 regulates Hsp90 acetylation and to examine the functional significance of such regulation. (Months 9-18)
We have found, using a combination of HDAC inhibitors and HDAC6 knock down cell lines that Hsp90 is deacetylated by HDAC6 (Figure 2 -attached manuscript) . The use of TrichostatinA (TSA) to inhibit HDAC6 function results in a marked increase in the acetylation of Hsp90 (Figure 2 ). This effect, however, is not recapitulated in cells treated with nicotinamide, a NAD-dependent deacetylase inhibitor (Data not shown). Additionally, Hsp90 is heavily acetylated in A459 and 293T cells that stably express an siRNA for HDAC6 (Figure 2 ). HDAC6 protein levels are drastically decreased in these cells, and Hsp90 shows a marked increase in acetylation. We have shown that Hsp90 is unable to bind certain client proteins in these cells, and are currently in the process of creating MCF7 knock down lines in order to examine the effects of HDAC6 on ErbB2. It appears that these knock-down cells show a decrease in anchorage independent growth by soft-agar assay ( Figure B) Additionally, we have shown that, in another context, Hsp90 acetylation is important to its functionality. Hsp90 is known to mediate gluccocorticoid receptor activity, and we have shown through a transcriptional assay, that HDAC6-mediated deacetylation is required for this activity (Figure 3 -attached manuscript) . Additonally, we have shown that this transcriptional decrease appears to be the result of the inability of GR to bind ligand (Figure 3) . Furthermore, GR cannot translocate into the nucleus of HDAC6 knock-down cells after stimulation (Figure 3 ). The ligand binding activity of GR can be restored by the addition of deacetylated Hsp90 ( Figure  C ). This proves that Hsp90 deacetylation is important for the proper functioning of Hsp90.
In addition to the above studies, we are currently in the process of mapping the acetylation sites on Hsp90. We have had no luck in determining the acetylation sites of Hsp90 using deletion mutants, and have now turned to a in vitro acetylation reaction using tritium to radiolabel Hsp90. These samples will then be examined by mass spec in order to determine acetylation sites. Our lab has previously used this technique to map acetylation sites on p53 and MDM2, so we are confident that we can do the same for Hsp90.
2. To determine the role of HDAC6 in EGFR down-modulation (Months 19-30) a. Examining the role of HDAC6 in the regulation of EGFR stability. Using our HDAC6 knock-down lines we have determined that the half-life of EGFR after ligand stimulation is markedly decreased in cells stably expressing HDAC6 siRNA when compared to control cells ( Figure D) . These are the same cells which show a drastic increase in acetylated Hsp90, thereby causing us to form a hypothesis, whereby HDAC6 deacetylates Hsp90, allows it to interact properly with EGFR, and causes a stabilization of the receptor. Furthermore, we have also shown that stimulation of cells with EGF causes the deacetylation of Hsp90 by HDAC6 (Figure E) . These data, coupled together imply that HDAC6-mediated deacetylation of Hsp90 controls the levels of EGFR in cells, and thus will regulate EGFRmediated responses to growth factor signaling. We are continuing to explore these avenues at this time by checking to see if Hsp90 acetylation status can effect either the chemotactic response of cells to EGF or the activity of EGFR-triggered signal transduction pathways.
b. Examining whether HDAC6/Hsp90 regulates the ubiquitination of EGFR. (Months 24-28)
We are currently working on this aim, but have no data at this time.
c. Determining the role ofHDAC6 in EGFR internalization and recycling. (Months 28-30)
We are currently exploring the possibility that HDAC6 effects endocytosis of receptors, but are only in the preliminary stages of this work. The increased degredation of EGFR in HDAC6 knockdown cells may be due to a deficiency in stability or a decrease in receptor recycling to the membrane. Further studies are needed to delineate between these two possibilities. [33] [34] [35] [36] We hypothesize that loss of HDAC6 will cause a decrease in chemotactic response to EGF. Preliminary results show that overexpression of HDAC6 causes an increase inresponse to growth factor stimulation in cells ( Figure F) . Interestingly, an Hsp90-binding deficient mutant ABUZ, is unable to cause this growth-factor-mediated increase in cell motility. 
3.

CONCLUSION:
The EGFR is found to be upregulated in 15-30% of breast cancers. Deregulation of EGFR function leads to uncontrolled growth factor signaling, which correlates with increasing tumor size, spreading of tumors to the lymph nodes and high grade metastasis. Since the constitutive activity of EGF receptors promotes breast cancer, it is important to determine the mechanism by which EGF receptors are regulated. It has recently been shown that Hsp90 is necessary for stabilization of the EGFR protein itself, and that the interaction of Hsp90 with target proteins requires that Hsp90 be deacetylated. We have shown that one of the eleven characterized human histone deacetylases, HDAC6, specifically binds Hsp90. The hypothesis we wish to test is whether HDAC6-mediated reversible acetylation of Hsp90 plays a critical role in EGFR activity and whether HDAC6 contributes to the carcinogenic potential of de-regulated EGFR.
We have now shown that HDAC6 and Hsp90 interact in response to EGF-mediated signaling.
This interaction led to the discovery of HDAC6 as an Hsp90 deacetylase. Interestingly, we have found that the deacetylation of Hsp90 is required for its proper functioning. Furthermore, it appears that HDAC6 plays a role in the general stability of EGFR in response to growth factor signaling, presumably through an Hsp90-dependent pathway. We are now continuing to characterize the important role of HDAC6 as an Hsp90 deacetylase, and are working to fully understand the functional consequences of Hsp90 deacetylation. In the next few months, we hope to apply these finding to experiments in the proposed cancer models to more fully understand the role of HDAC6 in tumor progression.
Due to the fact that EGFR signaling is a critical factor in breast cancer formation and metastasis, it is of great importance to understand the regulation of EGFR, and how changes in stability and internalization of this receptor contribute to carcinogenesis. The determination of HDAC6 as a factor that positively regulates EGFR signaling may provide an important drug target for future therapeutic strategies.
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1 A549 wt or KD cells were serum starved overnight in 0.2% FBS and then stimulated with 100 ng/ml EGF for the given amount of time. Cells were harvested and lysed according to previously described methods. IPs were performed using a-Hsp90 H1090 (Toft), and blots were immunoblotted with a-Acetyl Lysine (Yoshida). Note that basal levels of Hsp90 acetylation are higher in KD unstimulated KD lines (compare lanes 1 and 4). EGF stimulation triggers a deacetylation of Hsp90 (lanes 1-3) while this deacetylation does not occur in KD line (4-6). 
Introduction
The heat shock protein Hsp90 and its co-factors form molecular chaperone complexes that facilitate the structural maturation of its substrates, termed client proteins.
The Hsp90-assisted maturation of client proteins often leads to an enhanced activity and stability. Although initially recognized as a stress-induced protein, the realization that many Hsp90 targets are critical for normal and oncogenic signaling has identified Hsp90
as an important modulator in cell signaling and a promising target in cancer therapy (reviewed in (Neckers, 2002; Pratt and Toft, 2003) ). The emerging significance of Hsp90 in both normal and oncogenic signaling underlines the fundamental importance to understand how Hsp90 activity is regulated.
The prominent examples of Hsp90 client proteins include steroid hormone receptors and kinases important for oncogenesis (Richter and Buchner, 2001 ). Among many client proteins, the Hsp90-dependent maturation of glucocorticoid receptor (GR), a member of the steroid hormone receptor, is best characterized. GR mediates biological effects of glucocorticoid by acting as a transcription factor (Giguere et al., 1986) . Upon binding to glucocorticoid, GR becomes activated and translocates into the nucleus where it controls specific transcriptional programs. In the absence of its ligand, however, GR is inactive and resides in the cytoplasm where it associates with Hsp90 (Cadepond et al., 1991) . Importantly, it has been shown that the association with Hsp90 is critical for GR to assume a ligand-binding competent conformation. Both in vitro and in vivo analyses demonstrate that Hsp90, in conjunction with a selected set of co-chaperone proteins, is required for GR to bind hormone with high affinity (reviewed in (Pratt and Toft, 2003) ).
The study of Hsp90-dependent GR maturation has provided mechanistic insight into the 3 basic steps of chaperone complex-client protein assembly and the important functions of co-chaperones (Dittmar et al., 1997) . However, the critical question regarding whether and how Hsp90 itself is regulated in these processes is poorly understood.
Reversible protein acetylation has been characteristically linked to histone and chromatin-dependent processes. Recent studies, however, have revealed much broader arrays of biological processes that involve protein acetylation (reviewed in (Cohen and Yao, 2004) ). For example, the characterization of the deacetylase HDAC6, a member of the histone deacetylase family, has implicated protein acetylation in the regulation of microtubules, growth factor-induced chemotaxis and the processing of misfolded protein aggregates (Haggarty et al., 2003; Hubbert et al., 2002; Kawaguchi et al., 2003; Matsuyama et al., 2002; Zhang et al., 2003) . Consistent with these apparently nongenomic functions, HDAC6 is mainly localized to the cytoplasm (Hubbert et al., 2002; Verdel et al., 2000) . These observations suggest reversible protein acetylation controlled by HDAC6 might have important regulatory roles in cytoplasmically-based processes.
Identifying novel substrates for HDAC6 will be a critical step toward deciphering the general significance of protein acetylation in the cytoplasm.
In this report, we demonstrate that Hsp90 is a novel substrate of HDAC6 and its chaperone activity is regulated by acetylation. We show that HDAC6 and Hsp90 form a complex in vivo and that HDAC6 functions as an Hsp90 deacetylase. Inactivation of HDAC6 by pharmacological inhibition or by specific siRNA leads to hyperacetylation of Hsp90, the dissociation of an essential co-chaperone, p23, from Hsp90 and a loss of chaperone activity toward GR. We find that GR in HDAC6 deficient cells is defective in ligand binding, nuclear translocation and gene activation, revealing a failure of 4 chaperone-dependent maturation in the absence of functional HDAC6. Our results identify Hsp90/GR complex as a novel target of HDAC6 and suggest reversible acetylation as a critical mechanism in regulating Hsp90 molecular chaperone activity.
Results
HDAC6 associates with Hsp90 in vivo
To gain further insight into protein acetylation in the cytoplasm, we searched for cellular targets for HDAC6. Using an affinity trap approach, we identified Hsp90 as a prominent HDAC6 interacting partner by both mass spectrometry (data not shown) and direct immunoprecipitation, which shows that endogenous HDAC6 and Hsp90 can be abundantly and specifically co-immunoprecipitated from multiple cell lines ( Figure IA ).
To further characterize the HDAC6-Hsp9O interaction, we assessed whether mutations or pharmacological inhibitors that affect HDAC6 activity would influence its association with Hsp90. Full HDAC6 function requires both its deacetylase activity and a ubiquitinbinding activity, which is mediated by a unique zinc finger, termed the BUZ finger (Hubbert et al., 2002; Kawaguchi et al., 2003) . We found that inactivation of HDAC6 
HDAC6 regulates Hsp90 acetylation
An interaction between HDAC6 and Hsp90 is significant as Hsp90 was recently reported to be an acetylated protein (Yu et al., 2002) . We thus investigated the possibility that HDAC6 functions as an Hsp90 deacetylase. To this end, we first determined whether over-expression of HDAC6 can lead to Hsp90 deacetylation in vivo. As shown in Figure   2A Figure 3D , ii). In contrast, GR remains in the cytoplasm in the substantial majority (-80%) of HDAC6 knockdown cells following ligand addition ( Figure 3D, iv) . Thus, Hsp90-dependent GR ligand binding, nuclear translocation and transcriptional activity are all defective in HDAC6 knockdown cells. Together, these results argue that HDAC6-mediated deacetylation is required for Hsp90 chaperone function to activate GR.
Hsp90 hyperacetylation is correlated with the dissociation of functional chaperone-
GR complexes
The proper folding of GR by Hsp90 depends on the association of Hsp90 with a distinct set of co-chaperones into a chaperone complex (Reviewed in (Neckers, 2002; Pratt and Toft, 2003) ). To identify the molecular basis for the regulation of Hsp90 function via deacetylation, we determined whether Hsp90 acetylation affects Hsp90/cochaperone assembly. We focused on p23 (Johnson and Toft, 1994) , a co-chaperone that stabilizes the Hsp90-GR complex and is critical for GR ligand binding activity in vitro and in vivo (Dittmar et al., 1997; Morishima et al., 2003) . Co-immunoprecipitation assays demonstrate that Hsp90 associates with p23 in control cells ( Figure 4A , Lane 1).
However, Hsp90-p23 interactions are dramatically reduced in HDAC6 knockdown cells ( Figure 4A , Lane 4). TSA treatment, which induces Hsp90 hyperacetylation, also disrupts Hsp90-p23 interactions ( Figure 4A , lane 2). Conversely, TPXb treatment, which does not inhibit HDAC6 activity, has little effect ( Figure 4A , Lane 3). These results support the hypothesis that Hsp90 acetylation leads to the dissociation of p23 from Hsp90. As p23 is known to stabilize the Hsp90-GR complex (Dittmar et al., 1997) , we next examined whether acetylation affects Hsp90-GR complex formation. Indeed, the Hsp90 and GR interaction is significantly reduced in HDAC6 knockdown cells or by treatment with TSA ( Figure 4B , compare Lane 1, 2, and 3), providing a plausible mechanism for the observed GR defects. These results show that loss of HDAC6 activity leads to Hsp90 hyperacetylation, disassembly of the Hsp90 chaperone complex, and dissociation of the client protein GR.
Discussion
By promoting the activity and stability of many important signaling proteins, the molecular chaperone Hsp90 has recently emerged as a critical modulator in cell signaling and promising target in cancer therapy. Despite the apparent importance, the regulation of Hsp90 activity, chaperone complex formation and Hsp90-client protein interaction is not well understood. In this study, we identified HDAC6-regulated reversible acetylation as a novel mechanism that controls Hsp90 molecular chaperone function. Hsp90 acetylation and the dissociation of oncogenic client proteins from Hsp90 (Nimmanapalli et al., 2003; Xu et al., 2001) . Our study now identifies HDAC6 as the primary Hsp90 deacetylase targeted by those inhibitors ( Figure 2B) . Surprisingly, however, GR remains stable in HDAC6 knockdown cells even though it no longer stably associates with Hsp90 ( Figure 3C ). This is in contrast to the effect of the Hsp90 inhibitor geldanamycin (GA), which induces GR degradation (Whitesell and Cook, 1996) . These observations suggest that acetylation and geldanamycin, while both interfering with Hsp90 chaperone function towards GR, are not working through identical mechanisms.
Understanding how acetylation and geldanamycin differentially affect Hsp90 function could provide important insight into the regulation of chaperone-dependent client protein maturation and degradation.
Although the exact mechanism by which acetylation regulates Hsp90 function remains to be established, and there may be additional chaperone components subject to reversible acetylation, our findings support the hypothesis that acetylation acts by modulating Hsp90 chaperone complex formation (Figure 4 ). Significantly, a dramatic remodeling of the Hsp90 chaperone complex has been observed upon normal cell transition to a tumor state (Kamal et al., 2003) . This observation strongly suggests that the assembly of Hsp90 chaperone complexes is dynamically regulated and that its deregulation might play a key role for normal cells to undergo oncogenic transformation.
We propose that reversible acetylation, controlled by HDAC6 and a yet to be identified molecular chaperone acetyltransferase, may be a physiological modulator that regulates 
Materials and Methods
Cell lines -A549 and NIH-3T3 cell lines overexpressing HDAC6 wild type, ABUZ or catalytically inactive mutants were established through retroviral-mediated gene transfer.
A549 and 293T cells stably expressing an siRNA for HDAC6 were established as described previously (Kawaguchi et al., 2003) .
Antibodies -Rabbit polyclonal HDAC6 antibody DU227 was raised against a Cterminal HDAC6 peptide (DVKNAAHQNKFGEDMPHSH) followed by affinity purification and DU 184 has been described previously (Hubbert et al., 2002) . The production of antibodies for acetylated lysine (Komatsu et al., 2003) , Hsp90 (H1090) and p23 (JJ3) has been described (Johnson and Toft, 1994) . GR antibody was purchased from
Cell Signaling. S-14 antibody recognizing the N-terminus of HDAC6 was purchased from Santa Cruz.
Immunoprecipitation and immunostaining -Cells were lysed as described previously (Hubbert et al., 2002) . Hsp90 antibody was pre-incubated with rabbit-anti-mouse (Jackson Labs) and Protein-A Sepharose beads (Roche) for 10 minutes. The bead/antibody mix was added to 750ltg of whole cell lysate and incubated at 4°C for 3 hours. Samples were spun-down, washed 4 times with 150mM NETN (Hubbert et al., 2002 ) and subjected to SDS-PAGE followed by immunoblotting analysis.
Immuolocalization of GR and HDAC6 was performed as described previously (Hubbert et al., 2002 
